[Experiment study on the treatment of SCI based on HSV carried BDNF transgene technique].
OBJECTIVE
To explore the effect of brain derived neurotrophic factor (BDNF) transgenic treatment in rats following spinal cord injury (SCI).


METHODS
BDNF gene was cloned into plasmid then enveloped with human single herpes virus (HSV) to construct HSV carried BDNF transgenic recombinant. BDNF recombinant was injected into sciatic nerve to last label in motorneurous in the caudal cords, then ventral motor neurons were counted and the area of cell body was measured. The BBB scores representing motor function in hindlimbs was also recorded.


RESULTS
Five days were needed for the GFP-HSV to arrive motorneurons from sciatic nerve. BDNF release could increase the number of motroneurons and inhibit neuronal atrophy in injured spinal cord. BDNF administration also improves motor function in hindlimbs.


CONCLUSIONS
BDNF transgene carried by HSV is a useful strategy for the treatment of SCI, indicating its clinic implication in future treatment.
Cadre's Ward, Anhui Provincial Hospital, Hefei 230001, China.
Rong
R
Rong
Qi-Qin
QQ
Dan
Jia
J
Liu
Li-Qun
LQ
Hu
Ting-Hua
TH
Wang
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000096:biosynthesis* / Q000235:genetics; D003001:Cloning, Molecular; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008845:Microinjections; D009416:Nerve Regeneration; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D012584:Sciatic Nerve; D013119:Spinal Cord Injuries / Q000378:metabolism / Q000628:therapy*; D014162:Transfection
D019208:Brain-Derived Neurotrophic Factor; D011994:Recombinant Proteins